Cancer clinical trials in the region Nouvelle-Aquitaine

454 currently recruiting clinical trials
Region Nouvelle-Aquitaine
Phase 2 Lung cancer #NCT07016230 #2024-515847-47-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT07016230 #2024-515847-47-00
Required histologic types
Neuroendocrine tumor/carcinoma other than SCLC Stomach Thyroid cancer
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Lymphoma Brain tumors / Central nervous system tumors #NCT07015242 #2025-521144-38-00
Required histologic types
B cell lymphoma Other primary CNS tumor
Required histologic sub types
Primary cerebral lymphoma Primary CNS lymphoma
Required central nervous system lesions
Actives
Required number of previous lines of therapy
None
Excluded previous treatments
Car-T Allogeneic stem cell transplant
13 recruiting sites
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Endometrial cancer Sarcoma and GIST #NCT03624244
Required histologic types
Soft tissue sarcoma
Required histologic sub types
Other
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
18 recruiting sites
Centre Léon Bérard
Phase 2 Pancreas cancer #NCT07483983 #2025-522533-54-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12D
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07209111 #2025-521737-91-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 2 Stomach and esophageal cancer #NCT06059495
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Radiotherapy
11 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 2 Breast cancer #NCT07007559
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
6 recruiting sites
ALX Oncologie Inc
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT05503797 #2024-513578-23-00
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
HRAS KRAS G12C KRAS non G12C NRAS
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics
Phase 2 Brain tumors / Central nervous system tumors #NCT05503797 #2024-513578-23-00
Required genetic anomalies
BRAF
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Radiotherapy Radiochemotherapy
Excluded genetic anomalies
HRAS Other KRAS KRAS G12C KRAS G12D KRAS non G12C NRAS RAS
Excluded previous treatments
Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics